[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's stock over the past month. This price movement reflects broader market trends, as the Dow Jones was relatively flat amid ongoing U.S.-China tariff discussions. Johnson & Johnson's positive...",
    "url": "https://finnhub.io/api/news?id=bd942dfbe8ce88f2fce8b0afa9638de00ce2f7feecc6c0006e45f53da28745aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746811368,
      "headline": "Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback",
      "id": 134362261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's stock over the past month. This price movement reflects broader market trends, as the Dow Jones was relatively flat amid ongoing U.S.-China tariff discussions. Johnson & Johnson's positive...",
      "url": "https://finnhub.io/api/news?id=bd942dfbe8ce88f2fce8b0afa9638de00ce2f7feecc6c0006e45f53da28745aa"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Worries Shift to Prices From Trade. Trump’s Next Plan Could Sink Stocks.",
    "summary": "Pharma Worries Shift to Prices From Trade. Trump’s Next Plan Could Sink Stocks.",
    "url": "https://finnhub.io/api/news?id=ac42ac8bc85d73493d6981014a986e53594cf61c1bfd01b8285a21aa7f5271a9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746809460,
      "headline": "Pharma Worries Shift to Prices From Trade. Trump’s Next Plan Could Sink Stocks.",
      "id": 134382841,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Pharma Worries Shift to Prices From Trade. Trump’s Next Plan Could Sink Stocks.",
      "url": "https://finnhub.io/api/news?id=ac42ac8bc85d73493d6981014a986e53594cf61c1bfd01b8285a21aa7f5271a9"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=2fc83c556432825123456430cf0d4e06bfb749fc4d99be2fc3fb6172e60d4bba",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746794460,
      "headline": "Health Care Roundup: Market Talk",
      "id": 134383117,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=2fc83c556432825123456430cf0d4e06bfb749fc4d99be2fc3fb6172e60d4bba"
    }
  },
  {
    "ts": null,
    "headline": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
    "summary": "The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals.  J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028.  BTIG analyst Julian Harrison expects icotrokinra to  \"complement rather than disrupt\" market leaders, including J&J's Tremfya and AbbVie's Skyrizi.",
    "url": "https://finnhub.io/api/news?id=cb600eec5c855a10afd8da5ceb58f831fb8f17ce7757a6afb9c0a7265300c47d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746792845,
      "headline": "J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study",
      "id": 134362262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals.  J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028.  BTIG analyst Julian Harrison expects icotrokinra to  \"complement rather than disrupt\" market leaders, including J&J's Tremfya and AbbVie's Skyrizi.",
      "url": "https://finnhub.io/api/news?id=cb600eec5c855a10afd8da5ceb58f831fb8f17ce7757a6afb9c0a7265300c47d"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.",
    "url": "https://finnhub.io/api/news?id=0425b5855872ad4dd0658ad1d6be20ed2a4fee14080d086764923558f7de7b69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746792300,
      "headline": "Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis",
      "id": 134362263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.",
      "url": "https://finnhub.io/api/news?id=0425b5855872ad4dd0658ad1d6be20ed2a4fee14080d086764923558f7de7b69"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson expands efforts to champion the nursing workforce globally; New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges",
    "summary": "New Brunswick, N.J- Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts...",
    "url": "https://finnhub.io/api/news?id=1ba8a352780a7fbc3a2c466e522a29f76d2c136a617f42ba30de2b6d65f181b1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746790635,
      "headline": "Johnson & Johnson expands efforts to champion the nursing workforce globally; New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges",
      "id": 134345039,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "New Brunswick, N.J- Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts...",
      "url": "https://finnhub.io/api/news?id=1ba8a352780a7fbc3a2c466e522a29f76d2c136a617f42ba30de2b6d65f181b1"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?",
    "summary": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]",
    "url": "https://finnhub.io/api/news?id=537fcada9e0fd22074c171478fa60e6c15bca9c357e70cc72bbfdc5a8a981802",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746786804,
      "headline": "Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?",
      "id": 134335801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]",
      "url": "https://finnhub.io/api/news?id=537fcada9e0fd22074c171478fa60e6c15bca9c357e70cc72bbfdc5a8a981802"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive phase 3 data in psoriasis",
    "summary": "Johnson & Johnson has announced positive new data from the Phase 3 ICONIC-TOTAL study evaluating its icotrokinra in the treatment of adults and adolescents aged 12 years and older with...",
    "url": "https://finnhub.io/api/news?id=d385d8d05cba073b4e4e7c436af7c662106ee05230cef0bc53a9fc3e4f6bdd48",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746783622,
      "headline": "J&J: positive phase 3 data in psoriasis",
      "id": 134339377,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson has announced positive new data from the Phase 3 ICONIC-TOTAL study evaluating its icotrokinra in the treatment of adults and adolescents aged 12 years and older with...",
      "url": "https://finnhub.io/api/news?id=d385d8d05cba073b4e4e7c436af7c662106ee05230cef0bc53a9fc3e4f6bdd48"
    }
  },
  {
    "ts": null,
    "headline": "J&J's skin disease drug meets main goal in late-stage study",
    "summary": "Johnson & Johnson said onFriday its experimental psoriasis drug helped patients achieveclear or almost clear skin in a late-stage study. The once-daily oral drug, icotrokinra, was...",
    "url": "https://finnhub.io/api/news?id=b66869ccb13944db322d633e3051b7ee71cc4583a96c6ae8224b14183033f3dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746779408,
      "headline": "J&J's skin disease drug meets main goal in late-stage study",
      "id": 134337549,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson said onFriday its experimental psoriasis drug helped patients achieveclear or almost clear skin in a late-stage study. The once-daily oral drug, icotrokinra, was...",
      "url": "https://finnhub.io/api/news?id=b66869ccb13944db322d633e3051b7ee71cc4583a96c6ae8224b14183033f3dc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces New Data from the Phase 3 ICONIC-TOTALa Study Investigating icotrokinra (JNJ-2113)",
    "summary": "Johnson & Johnson announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra , the first-in-class investigational targeted oral peptide that selectively blocks the IL-23...",
    "url": "https://finnhub.io/api/news?id=5f988d6d3a5daec26e3b1a0f0ad59de233baf5881b27fadbdea403f402f1d588",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746777900,
      "headline": "Johnson & Johnson Announces New Data from the Phase 3 ICONIC-TOTALa Study Investigating icotrokinra (JNJ-2113)",
      "id": 134338705,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra , the first-in-class investigational targeted oral peptide that selectively blocks the IL-23...",
      "url": "https://finnhub.io/api/news?id=5f988d6d3a5daec26e3b1a0f0ad59de233baf5881b27fadbdea403f402f1d588"
    }
  },
  {
    "ts": null,
    "headline": "Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
    "summary": "Zymeworks Inc (ZYME) reports a significant revenue increase and strong cash position, while navigating rising expenses and strategic uncertainties.",
    "url": "https://finnhub.io/api/news?id=3de5d3e5aa284d75334d9ce8ccd3f32435b5de8f622d9d6e9cc0ae172cf8285d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746776731,
      "headline": "Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
      "id": 134335802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zymeworks Inc (ZYME) reports a significant revenue increase and strong cash position, while navigating rising expenses and strategic uncertainties.",
      "url": "https://finnhub.io/api/news?id=3de5d3e5aa284d75334d9ce8ccd3f32435b5de8f622d9d6e9cc0ae172cf8285d"
    }
  }
]